Study shows direct relationship between Alzheimer s tau protein and Cholesterol

60.00% credibility
 
Related

The piglet who looks like an Elephant

Atma
1198 points

This video of a mother dressing up her triplets is a must watch!

Atma
1306 points



Most recent

Cuáles son los ciberataques más comunes en época de coronavirus

MaríaGeek
10 points

Julia Ward Howe

PENSAMIENTO LIBRE
38 points

Periodista Andrea González-Villablanca finaliza sus estudios en la UNCTAD, Ginebra

ESNOTICIA.COM
14 points

Mi mujer nunca me creyó

Henri Monzó Catalá
10 points

Viejo, sí, pero más a gusto que un marrano en un charco

Enrique TF
8 points

Las aventuras nos impulsan a seguir viviendo

Enrique TF
14 points

¿QUE HA HECHO MAL EL ESTADO CON EL EJERCITO?

PENSAMIENTO LIBRE
10 points

¿Por qué requiere tanto tiempo conseguir una vacuna contra el coronavirus?

Actualidad
416 points

Un evento online reunirá durante siete horas en directo a técnicos de toda Latinoamérica para diseña

CYPE
8 points

Éramos felices y no lo sabíamos

PENSAMIENTO LIBRE
36 points
SHARE
TWEET
We have known for some years that Alzheimer’s disease is characterised by two types of lesions, amyloid plaques and degenerated tau protein. Cholesterol plays an important role in the physiopathology of this disease. Two French research teams (Inserm/CEA/University of Lille/University of Paris-Sud ) have just shown, in a rodent model, that overexpressing an enzyme that can eliminate excess cholesterol from the brain may have a beneficial action on the tau component of the disease, and completely correct it. This is the first time that a direct relationship has been shown between the tau component of Alzheimer’s disease and cholesterol. This work is published in the 10 September 2015 issue of Human Molecular Genetics.

Study shows direct relationship between Alzheimer   s tau protein and Cholesterol

xcess brain cholesterol cannot freely cross the blood-brain barrier; to be eliminated it must be converted into 24-hydroxycholesterol (24-OHC) by the enzyme CYP46A1 (cholesterol-24-hydroxylase). At Inserm Unit 1169, Nathalie, Cartier, coordinator of this work, and Patrick Aubourg, director of the unit, proposed the hypothesis that increasing the efflux of cholesterol from the brain by overexpressing CYP46A1 might have a beneficial effect on the elements of Alzheimer pathology.

The first step in this work made it possible to show that injecting a viral vector, AAV-CYP46A1, effectively corrects a mouse model of amyloid pathology of the disease, the APP23 mouse. CYP46A1 thus appears to be a therapeutic target for Alzheimer’s disease.

Conversely, in vivo inhibition of CYP46A1 in the mice, using antisense RNA molecules delivered by an AAV vector administered to the hippocampus, induces an increase in the production of Aß peptides, abnormal tau protein, neuronal death and hippocampal atrophy, leading to memory problems. Together these elements reproduce a phenotype mimicking Alzheimer’s disease.

These results demonstrate the key role of cholesterol in the disease, and confirm the relevance of CYP46A1 as a potential therapeutic target (work published in Brain on 3 July 2015).

Taken together, this work now enables the research team coordinated by Nathalie Cartier, Inserm Research Director, to propose a gene therapy approach for Alzheimer’s disease: intracerebral administration of a vector, AAV-CYP46A1, in patients with early and severe forms (1% of patients, familial forms) for whom there is no available treatment.

“To achieve this objective, we are carrying out all the preclinical steps of development and validation of the tools (vector, neurosurgical protocol, elements of monitoring) for demonstrating the efficacy and tolerance of the strategy, in order to submit an application for authorisation of a clinical trial,” explains Nathalie Cartier.

Fuente: neurosciencenews.com
SHARE
TWEET
To comment you must log in with your account or sign up!
Featured content